Fulcrum Therapeutics (FULC) Enterprise Value (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Enterprise Value of -$333.3 million for Q1 2026, down 690.26% year-over-year from $56.5 million in Q1 2025, and down 68.74% quarter-over-quarter from -$197.5 million in Q4 2025.
Fulcrum Therapeutics (FULC) Enterprise Value (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Enterprise Value data on file, last reported at -$333.3 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$333.3 million, down 690.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$333.3 million (down 690.26% YoY), and the FY2025 annual result was -$197.5 million, up 18.04% from the prior year.
- Enterprise Value retreated to -$333.3 million in Q1 2026 per FULC's latest filing, from -$197.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$30.1 million in Q3 2023 and troughed at -$333.3 million in Q1 2026.
- A 5-year average of -$106.4 million and a median of -$47.1 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2026: Enterprise Value surged 66.93% in 2022, then tumbled 690.26% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$35.1 million in 2022, then plunged by 573.03% to -$236.2 million in 2023, then decreased by 2.03% to -$241.0 million in 2024, then rose by 18.04% to -$197.5 million in 2025, then sank by 68.74% to -$333.3 million in 2026.
- Business Quant data shows FULC's Enterprise Value at -$333.3 million in Q1 2026, -$197.5 million in Q4 2025, and -$47.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -584.73 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | -333.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -333.32 Mn |
| Dec 31, 2025 | -197.53 Mn |
| Sep 30, 2025 | -47.08 Mn |
| Jun 30, 2025 | -214.11 Mn |
| Mar 31, 2025 | -42.18 Mn |
| Dec 31, 2024 | -241.02 Mn |
| Sep 30, 2024 | -72.63 Mn |
| Jun 30, 2024 | -86.70 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Dec 31, 2023 | -236.22 Mn |
| Sep 30, 2023 | -30.08 Mn |
| Jun 30, 2023 | -33.97 Mn |
| Mar 31, 2023 | -34.73 Mn |
| Dec 31, 2022 | -35.10 Mn |
| Sep 30, 2022 | -90.94 Mn |
| Jun 30, 2022 | -40.15 Mn |
| Mar 31, 2022 | -33.31 Mn |
| Dec 31, 2021 | -35.41 Mn |
| Sep 30, 2021 | -65.47 Mn |
| Jun 30, 2021 | -56.78 Mn |